Paolo Tarantino

Company: Dana-Farber Cancer Institute

Job title: Advanced Fellow

Seminars:

Rethinking Patient Selection for Addressing Unique Toxicity Challenges From ADC Therapy – Balancing Risk & Access 1:02 pm

Current ADC trials often exclude high-risk patients due to concerns about toxicity – but is this the best approach? This session will explore how ADCs work and why they cause toxicity, how we can better predict and manage adverse events in the clinic (with a focus on breast cancer), and how new molecules may help…Read more

day: Pre-Conference Workshop Day